Halozyme Therapeutics | HALO - Cost Of Sales

Stock Price
68.29
Daily Change
-0.44 -0.64%
Monthly
-0.18%
Yearly
26.63%
Q2 Forecast
65.77

Halozyme Therapeutics reported $108.75M in Cost of Sales for its fiscal quarter ending in March of 2026.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 24.79M 1.43M Mar/2026
Agios Pharmaceuticals USD 1.32M 560K Mar/2026
Alnylam Pharmaceuticals USD 211.12M 56.6M Mar/2026
Amarin USD 26.05M 1.41M Dec/2025
Amgen USD 1.6B 187M Mar/2026
Baxter International USD 1.81B 587M Mar/2026
Cara Therapeutics USD 0 0 Mar/2025
Cytokinetics USD 160K 104.24M Mar/2026
Eli Lilly USD 3.58B 205M Mar/2026
Esperion Therapeutics USD 27.85M 13.43M Dec/2025
Halozyme Therapeutics USD 108.75M 6.6M Mar/2026
Intrexon USD 1.01M 344K Jun/2024
Ionis Pharmaceuticals USD 3M 5M Mar/2026
MannKind USD 39.58M 5.94M Mar/2026
Minerva Neurosciences 386K 31K Jun/2024
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Pfizer USD 4.59B 1.7B Mar/2026
Rigel Pharmaceuticals USD 8.03M 5.22M Sep/2024
United Therapeutics USD 133.4M 341.3M Mar/2026
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024